Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 14/20 | 0.73 |
| ▸ | PDCD1 | Q15116 | 10/20 | 0.73 |
| ▸ | FASN | P49327 | 1/20 | 0.35 |
| ▸ | WNT3A | P56704 | 1/20 | 0.34 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.33 |
| ▸ | PRKDC | P78527 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19549737 | 0.80 | PDCD1 (1.00) | CD274PDCD1 | |
| SCHEMBL19549728 | 0.75 | CD274 (0.81) | CD274PDCD1CYP3A4ADRA2A | |
| SCHEMBL11515152 | 0.72 | WNT3A (0.46) | CD274PDCD1WNT3ATNKS2CYP3A4 | |
| SCHEMBL24187984 | 0.70 | PDCD1 (0.60) | CD274PDCD1FASNADRA2AADRA2B | |
| SCHEMBL24187953 | 0.70 | PDCD1 (0.62) | CD274PDCD1CYP3A4 | |
| SCHEMBL24187941 | 0.70 | PDCD1 (0.62) | CD274PDCD1FASNCYP3A4 | |
| SCHEMBL28646193 | 0.70 | PDCD1 (0.62) | CD274PDCD1FASNCYP3A4 | |
| SCHEMBL12492799 | 0.69 | PDCD1 (0.68) | CD274PDCD1CYP3A4 | |
| SCHEMBL13476751 | 0.66 | PDCD1 (0.54) | CD274PDCD1FASN | |
| SCHEMBL24188353 | 0.65 | CD274 (0.56) | CD274PDCD1ADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210017175-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2021-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210017175-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | CD274 88/4885PDCD1 157/4885FASN 1882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.